Second-generation BI analogues, insulin glargine 300 U/mL (Gla-300) and insulin degludec (IDeg), have been increasingly used for diabetes management among clinicians as they provide a wide range of advantages including longer duration and stable insulin action, and comparable glycemic efficacy with lower hypoglycemia risk compared to the first-generation BI analogues [7-10]. Here, INS is linked to Hypoglycemia.